Skin cancer patients could have a better prognosis if their T cells send messages from five specific genes in their immune response to drugs given to treat the disease suggests the findings of new research led by the University of Birmingham.
The research, carried out in mice, cells in the laboratory, and using publicly available data from patients with advanced melanoma before and after treatment with Nivolumab therapy, was published in the journal Immunity.
T cells are white blood cells that protect the body from harm from viruses, bacteria, and cancer cells and explore their environments by using their T cell receptor (TCR) to recognise fragments - called antigens - of microbes or damaged cancer cells.
The TCR controls the behaviour of the T cell and can send messages to the T cells' command centre to kick-start an immune response. This process is important for vaccine research and treatment of autoimmune conditions but is particularly of interest for cancer treatments to improve the anti-tumour function of T cells.
The researchers carried out the study to better understand how the amount of antigen controls how the TCR sends messages to the T cells' command centre, and how this affects the type of immune response. They wanted to explore how antigen amounts control the expression of so-called 'immune checkpoints' that act as brakes on immune responses. It is these immune brakes, such as one called PD1, that are the target of drugs that seek to increase the immune response in cancer immunotherapy.
Lead author Dr David Bending, of the University of Birmingham's Institute of Immunology and Immunotherapy, explained: "Through our research, we discovered that the amount of antigen determined how many immune checkpoints or immune brakes a T cell had on its cell surface.
"When we exposed T cells to the highest amounts of antigen, they stopped sending signals to their command centre, and this was because they had increased the number of immune brakes, which shut down the messengers. This made these T cells unable to respond to antigens for a period."
By blocking one of the immune brakes, called PD1, the researchers were able to re-awaken some of these 'unresponsive' T cells. They found that these re-awakened T cells not only started sending messages to their command centres, but the messages they sent were louder and clearer.
"The response from the command centre was that the T cells started to increase the number of messages from five specific genes," added Dr Bending. "By looking for the messages from these five genes, we were able to show that these stronger and louder messages were increased in melanoma patients who survived for longer on drugs that block the immune brake PD1. We think that this means that those cancer patients whose immune cells can send messages from these five genes in response to drugs that target PD1, a good outcome is far more likely."
The researchers said their finding shows that the immune system likely requires an optimal level of stimulation to mount the most effective immune response in skin cancer patients.
Dr Bending added: "Our research gives us an interesting insight into fundamental workings of the immune system. It suggests that both the amount of antigen around a T cell and also the number of immune brakes the T cells have at their surface are very important in controlling immune responses. Furthermore, we have shown that we can alter the balance of the immune response through stopping some of these immune brakes, which results in a stronger T cell response."
The study has generated a new potential readout to monitor patients on drugs targeting PD1 in cancer. It also may be useful for exploring the potential of combinations of drugs that target multiple immune checkpoints to try to further re-awaken T cells in cancer patients.